These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34575390)

  • 41. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain.
    Benavent D; Franco-Gómez K; Plasencia-Rodriguez C; Novella-Navarro M; Bogas P; Nieto R; Monjo I; Nuño L; Villalba A; Peiteado D; Balsa A; Navarro-Compán V
    BMJ Open; 2022 Apr; 12(4):e057850. PubMed ID: 35487753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease activity indexes might not capture the same disease aspects in males and females with ankylosing spondylitis: A real-world nationwide analysis.
    Fernández-Carballido C; Jovaní V; Catalán EB; Moreno-Ramos MJ; Sanz Sanz J; Gallego A; García Vivar ML; Rodríguez-Heredia JM; Sanabra C; Sastré C
    Front Med (Lausanne); 2022; 9():1078325. PubMed ID: 36619648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease control in patients with ankylosing spondylitis in real clinical practice in Spain: Results of the MIDAS study.
    de Miguel E; Fernández-Carballido C; Gratacós J; Pablos JL; Juanola X; Ariza R; Terradas-Montana P; Sanabra C; Sastré C;
    Reumatol Clin (Engl Ed); 2023 Feb; 19(2):99-105. PubMed ID: 36739123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
    Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
    Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis.
    Cinar M; Yilmaz S; Cinar FI; Koca SS; Erdem H; Pay S; Dinc A; Yazici Y; Simsek I
    Rheumatol Int; 2015 Sep; 35(9):1575-80. PubMed ID: 25794571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula.
    Aranda-Valera IC; Garrido-Castro JL; Ladehesa-Pineda L; Vazquez-Mellado J; Zarco P; Juanola X; Gonzalez-Navas C; Font-Ugalde P; Castro-Villegas MC
    Rheumatology (Oxford); 2020 Jul; 59(7):1545-1549. PubMed ID: 31628804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
    Marona J; Sepriano A; Rodrigues-Manica S; Pimentel-Santos F; Mourão AF; Gouveia N; Branco JC; Santos H; Vieira-Sousa E; Vinagre F; Tavares-Costa J; Rovisco J; Bernardes M; Madeira N; Cruz-Machado R; Roque R; Silva JL; Marques ML; Ferreira RM; Ramiro S
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 32144137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study.
    Rusman T; Nurmohamed MT; Hoekstra S; van Denderen CJ; van Vollenhoven RF; Boers M; Ter Wee MM; van der Horst-Bruinsma IE
    Scand J Rheumatol; 2022 Nov; 51(6):506-512. PubMed ID: 34726125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
    Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
    Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?
    Kilic G; Kilic E; Ozgocmen S
    Int J Rheum Dis; 2017 Sep; 20(9):1201-1211. PubMed ID: 27309497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).
    Solmaz D; Yildirim T; Avci O; Tomas N; Akar S
    Clin Rheumatol; 2016 Jul; 35(7):1753-8. PubMed ID: 26670454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical significance of high sensitivity C-reactive protein for evaluating the efficacy of etanercept in active ankylosing spondylitis].
    Zhang J; Huang F; Zhang J; Deng X; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(3):204-7. PubMed ID: 24731464
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
    Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
    J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.
    Aydin SZ; Can M; Atagunduz P; Direskeneli H
    Clin Exp Rheumatol; 2010; 28(5):752-5. PubMed ID: 20863448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.